[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100536884":3},{"organization":4,"outcomesModule":7,"designInfo":187,"detailedDescription":195,"studyPopulation":192,"armGroups":196,"interventions":207,"overallOfficials":192,"centralContacts":212,"locations":221,"responsibleParty":237,"collaborators":241,"id":259,"slug":192,"hasResults":260,"nctId":261,"briefTitle":262,"officialTitle":263,"acronym":264,"eligibilityCriteria":265,"healthyVolunteers":260,"sex":266,"minAge":267,"maxAge":268,"enrollmentInfo":269,"targetDuration":192,"studyType":272,"phases":273,"briefSummary":275,"conditions":276,"keywords":278,"overallStatus":224,"whyStopped":192,"lastUpdateSubmitDate":283,"lastUpdatePostDateStruct":284,"startDateStruct":287,"completionDateStruct":289,"leadSponsor":291,"locationsCount":292},{"fullName":5,"class":6},"UMC Utrecht","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":22,"otherOutcomes":137},[9,13,16,18,20],{"measure":10,"description":11,"timeFrame":12},"Health-Related Quality of Life","Measured with the summary scale of the EORTC QLQ-C30; min 0- max 100 points; higher scores mean better quality of life","Week 0 - Week 12",{"measure":14,"description":15,"timeFrame":12},"A standardized symptom score, per patient, based on the individual patient's main side-effect defined at baseline","Side-effect 1: Fatigue measured with EORTC QLQ-FA12. According to a standardization procedure the symptom score of all patients will be combined into one symptom score..",{"measure":14,"description":17,"timeFrame":12},"Side-effect 2: Anxiety and depressive symptoms measured with Patient Health Questionnaire Anxiety and Depression Scale (PHQ-ADS). According to a standardization procedure the symptom score of all patients will be combined into one symptom score.",{"measure":14,"description":19,"timeFrame":12},"Side-effect 3: Physical functioning measured with EORTC QLQ-C30 physical function scale According to a standardization procedure the symptom score of all patients will be combined into one symptom score.",{"measure":14,"description":21,"timeFrame":12},"Side-effect 4: CPIN measured with EORTC QLQ-CPIN20. According to a standardization procedure the symptom score of all patients will be combined into one symptom score.",[23,27,30,33,36,39,43,46,49,52,55,58,61,65,68,71,74,78,81,84,87,90,93,96,99,102,105,108,111,115,118,121,123,125,128,131,134],{"measure":24,"description":25,"timeFrame":26},"Health-related quality of life","Domains of the EORTC QLQ-C30 (except summary score)","Week 0 - Week 36",{"measure":28,"description":29,"timeFrame":26},"Fatigue","Cancer-Related fatigue measured with the EORTC-FA12",{"measure":31,"description":32,"timeFrame":26},"Anxiety and Depression","Anxiety and depressive symptoms measured with the Patient Health Questionnaire Anxiety and Depression Scale (PHQ-ADS)",{"measure":34,"description":35,"timeFrame":26},"CIPN_1","Chemotherapy-induced peripheral neuropathy measured with EORTC QLQ-CIPN-20",{"measure":37,"description":38,"timeFrame":26},"CIPN_2","2 items of the Patient Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)",{"measure":40,"description":41,"timeFrame":42},"Sleep","Pittsburgh Sleep Quality Index (PSQI)","0-36 weeks",{"measure":44,"description":45,"timeFrame":26},"Pain prevalence and type","EORTC QLQ-SURV100",{"measure":47,"description":48,"timeFrame":26},"Cognitive problems","Functional Assessment of Cancer Therapy-Cognitive Function (FACT-Cog)",{"measure":50,"description":51,"timeFrame":26},"Work limitations","Work Limitations Questionnaire (WLQ)",{"measure":53,"description":54,"timeFrame":26},"Body image","Body Image Scale (BIS)",{"measure":56,"description":57,"timeFrame":42},"Fear of cancer recurrence","EORTC QLQ-surv100",{"measure":59,"description":60,"timeFrame":26},"Habitual physical activity","Modified Godin-Shephard Leisure-Time Physical Activity Questionnaire",{"measure":62,"description":63,"timeFrame":64},"Aerobic capacity on bike","Steep ramp test","Week 0 - Week 24",{"measure":66,"description":67,"timeFrame":64},"Aerobic capacity on step","Chester step test",{"measure":69,"description":70,"timeFrame":64},"Handgrip strength","Handgrip test",{"measure":72,"description":73,"timeFrame":64},"Upper body muscle strength","Chest press",{"measure":75,"description":76,"timeFrame":77},"Lower body muscle strength","Leg press","0-24 weeks",{"measure":79,"description":80,"timeFrame":64},"Sit to stand test","30 sec sit to stand test- function test",{"measure":82,"description":83,"timeFrame":64},"Physical function","Time Up and Go (TUG) test",{"measure":85,"description":86,"timeFrame":64},"Balance","Single leg stance test with open and closed eyes",{"measure":88,"description":89,"timeFrame":42},"Physical activity","Measured with an activity tracker (Fitbit)",{"measure":91,"description":92,"timeFrame":77},"Blood pressure","Measured twice with blood pressure device",{"measure":94,"description":95,"timeFrame":64},"Resting heart rate","Measured with blood pressure device",{"measure":97,"description":98,"timeFrame":64},"Weight","Weight. in KG",{"measure":100,"description":101,"timeFrame":64},"Height","Height in cm",{"measure":103,"description":104,"timeFrame":64},"Waist circumference","Waist circumference in cm",{"measure":106,"description":107,"timeFrame":64},"Hip circumference","Hip circumference in cm",{"measure":109,"description":110,"timeFrame":64},"Body composition","Fat mass and fat free mass with bio-impedance - three centers",{"measure":112,"description":113,"timeFrame":114},"Inflammatory state","The specific inflammatory markers (e.g., cytokines, interleukins) will be decided at the time-point of analyses to be able to include factors according to up-to-date insights and use state-of the art platforms; we will for example use the Olink PEA platform (Oncology and Inflammation Array)","0-12 weeks",{"measure":116,"description":117,"timeFrame":114},"Growth factors","The specific growth factors will be decided at the time-point of analyses to be able to include factors according to up-to-date insights and use state-of the art platforms ; we will for example use the Olink PEA platform (Oncology and Inflammation Array)",{"measure":119,"description":120,"timeFrame":12},"CRP","Blood cell count",{"measure":122,"description":120,"timeFrame":114},"Hemoglobin",{"measure":124,"description":120,"timeFrame":114},"Leucocyte counts",{"measure":126,"description":127,"timeFrame":26},"Quality-adjusted life years","EuroQol-5D-5L",{"measure":129,"description":130,"timeFrame":26},"Health-care, patient and family costs","Modified Medical Consumption Questionnaire (iMCQ)",{"measure":132,"description":133,"timeFrame":26},"Productivity losses","Modified Productivity Cost Questionnaire (iPCQ)",{"measure":135,"description":136,"timeFrame":26},"Exercise-related (serious) adverse events","Via CASTOR app before and after each session; asked at and at the study visits.",[138,142,144,147,150,153,155,157,160,163,165,169,172,175,178,181,183,185],{"measure":139,"description":140,"timeFrame":141},"Participants experience of sensor-based guidance","Questionnaires - substudy control patients Cologne","Week 12- Week 24",{"measure":143,"description":140,"timeFrame":141},"Trainer experience of sensor-based guidance",{"measure":145,"description":146,"timeFrame":141},"Compliance sensor-based guidance","% of sessions that patients wear the sensor - substudy control patients Cologne",{"measure":148,"description":149,"timeFrame":141},"Technical feasibility of sensor-based guidance","% of successful live transfer of sensor data - substudy control patients Cologne",{"measure":151,"description":152,"timeFrame":141},"Aerobic capacity","Chester Step test - substudy live-remote testing",{"measure":72,"description":154,"timeFrame":141},"Push-up test - substudy live-remote testing",{"measure":75,"description":156,"timeFrame":141},"30 sec sit-to stand test - substudy live-remote testing",{"measure":158,"description":159,"timeFrame":141},"Core muscle strength","Plank position holding time - substudy live-remote testing",{"measure":161,"description":162,"timeFrame":141},"Physical functioning","Time Up and Go (TUG) test - substudy live-remote testing",{"measure":85,"description":164,"timeFrame":141},"Single leg stance test with open and closed eyes - substudy live-remote testing",{"measure":166,"description":167,"timeFrame":168},"Socio-demographics","Self-designed questionnaire","baseline",{"measure":170,"description":171,"timeFrame":168},"Self-efficacy","General Self-Efficacy Scale",{"measure":173,"description":174,"timeFrame":168},"Social Support","Index of Sojourner Social Support (ISSS)",{"measure":176,"description":177,"timeFrame":168},"Medical history","Interview",{"measure":179,"description":177,"timeFrame":180},"Concomitant diseases","Week 0- Week 36",{"measure":182,"description":177,"timeFrame":180},"Cancer + concomitant medication",{"measure":184,"description":177,"timeFrame":168},"Cancer characteristics",{"measure":186,"description":177,"timeFrame":168},"Cancer treatment history",{"allocation":188,"interventionModel":189,"interventionModelDescription":190,"primaryPurpose":191,"observationalModel":192,"timePerspective":192,"maskingInfo":193},"RANDOMIZED","PARALLEL","RCT with two study arms: exercise group and wait list control group","SUPPORTIVE_CARE",null,{"masking":194,"maskingDescription":192,"whoMasked":192},"NONE","SUMMARY\n\nRationale:\n\nMany cancer patients suffer from long-term treatment-related side-effects like fatigue, low physical functioning, anxiety and\u002For depressive symptoms, and chemotherapy-induced peripheral neuropathy (CIPN). There is convincing evidence on the beneficial effects of general exercise interventions on these side-effects. However, studies to date generally fail to specifically screen for (long-term) side-effects at baseline and tailor the intervention to these specific side-effects, although larger exercise effects are observed in patients with a high symptom burden at baseline (e.g., with higher levels of fatigue). Larger effects of exercise are also observed for supervised exercise compared to unsupervised exercise. However, two of the most common barriers for attending and complying with supervised exercise are travel distance and time. An effective approach might be to provide live-remote supervision for exercise interventions. In this scenario, patients can receive guidance from a certified exercise specialist through a video-conferencing platform such as Zoom, while performing exercises within the comfort of their own homes. Currently, the effectiveness of live-remote exercise in cancer patients has not been established.\n\nObjective:\n\nThe primary objective of the LION RCT is to assess the (cost-)effectiveness of a personalized, live-remote exercise intervention for cancer survivors on Health-Related Quality of Life (HRQOL) and the participants' main, self-reported side-effect. The four side-effects targeted in this study are: 1) fatigue, 2) perceived low physical functioning in daily life, 3) anxiety and\u002For depressive symptoms, and 4) CIPN.\n\nStudy design:\n\nThe LION RCT is a randomized controlled trial with two study arms: an exercise group (12 weeks) and a wait list control group. A super umbrella design will be used, allowing us to evaluate four exercise modalities (i.e., exercise modules based on participants' main side-effect) in a wide variety of cancer survivors.\n\nStudy population:\n\nFor this study, 350 adult cancer survivors treated with systemic chemotherapy (≥ 12 weeks to 1 year after completion of primary treatment of invasive cancer with curative intent) will be recruited independent of their primary cancer diagnosis. Participants will have reported at least one of the following side-effects: fatigue, low physical functioning in daily life, anxiety and\u002For depressive symptoms, CIPN. Additionally, participants need to be relatively physically inactive, i.e., perform ≤210 minutes\u002Fweek of moderate-to-vigorous leisure and sports activities.\n\nIntervention:\n\nThe intervention consists of three live-remote exercise sessions per week. Participants randomized to the exercise group receive the intervention after the baseline visit and the wait list control participants after the 12-week follow-up visit. A modular approach will be used to tailor the intervention to each participant's specific main side-effect. Each participant will receive the same base module (twice a week) to address HRQOL and in addition one out of four specific modules (once a week) addressing their individual main side-effect. In addition to the live-remote training, participants will be provided with the LION app and an activity tracker (Fitbit) at the start of the intervention to support exercise beyond the supervised program, during holidays and after the end of the intervention. In addition to exercise, the intervention also has an educational component including information about general effects of exercise for cancer patients and why exercise is important for specific side-effects. We consider the provision of such education as an integral part of adequate exercise programming.\n\nAfter the intervention period of 12 weeks, we follow the patients until 36 weeks. In this follow-up period, also two sub studies take place:\n\n1. Sensor-based guidance sub study (only control patients from Cologne)\n2. Live-remote physical fitness and function testing (in all control patients; all sites)",[197,203],{"label":198,"type":199,"description":200,"interventionNames":201},"Exercise group","EXPERIMENTAL","Participants will be offered three live-remote exercise training sessions per week. Each participant in the trial will be provided with the base module twice a week, which will involve a personalized training intensity. This module aims at targeting the participants' HRQOL, which is the first primary endpoint of the trial. Additionally, each participant will receive one out of four specific modules once a week to address their individual main side-effect (based on shared decision-making (SDM)) (second primary outcome). The intervention also includes an educational component about exercise and cancer.",[202],"Behavioral: Exercise group",{"label":204,"type":205,"description":206,"interventionNames":192},"Wait list control group","NO_INTERVENTION","Regular care The control group will receive the same exercise program after the 12 weeks intervention period",[208],{"type":209,"name":198,"description":210,"armGroupLabels":211,"otherNames":192},"BEHAVIORAL","Live-remote exercise sessions, personalized to the patients main side-effect",[198],[213,218],{"name":214,"role":215,"phone":216,"phoneExt":192,"email":217},"Evelyn Monninkhof, PhD","CONTACT","+3161118187","e.monninkhof@umcutrecht.nl",{"name":219,"role":215,"phone":216,"phoneExt":192,"email":220},"Anne May, PhD","a.m.may@umcutrecht.nl",[222],{"facility":223,"status":224,"city":225,"state":192,"zip":192,"country":226,"countryCode":227,"cosmosGeoPoint":228,"geoPoint":233,"contacts":234},"University Medical Center Utrecht","RECRUITING","Utrecht","Netherlands","NL",{"type":229,"coordinates":230},"Point",[231,232],5.12222,52.09083,{"lat":232,"lon":231},[235],{"name":236,"role":215,"phone":192,"phoneExt":192,"email":192},"Anne May, Prof.",{"type":238,"investigatorFullName":239,"investigatorTitle":240,"investigatorAffiliation":5,"oldNameTitle":192,"oldOrganization":192},"PRINCIPAL_INVESTIGATOR","Dr. Anne May","Prof. Dr.",[242,244,246,249,251,253,255,257],{"name":243,"class":6},"German Cancer Research Center",{"name":245,"class":6},"German Sport University, Cologne",{"name":247,"class":248},"Cabrini Health (CAB), Malvern, Australia","UNKNOWN",{"name":250,"class":248},"Karolinska Institute (KI), Stockholm, Sweden",{"name":252,"class":6},"The Netherlands Cancer Institute",{"name":254,"class":248},"Heidelberg University Clinic and National Center for Tumor Diseases, Heidelberg, Germany",{"name":256,"class":248},"Fundacion Onkologikao (ONK), San Sebastian, Spain",{"name":258,"class":248},"Associação de Investigação e Cuidados de Suporte em Oncologia (AISCO), Nova de Gaia, Portugal","100536884",false,"NCT06270628","Personalized Live-remote Exercise Training for Cancer Survivors","Demonstrating the (Cost-)Effectiveness of a Personalized Live-remote Exercise Intervention for Cancer Survivors Using a Super Umbrella Randomized Controlled Trial: the LION RCT","LION","Inclusion Criteria:\n\nTo be eligible to participate in this study, a subject must be:\n\n* 18 years of age or older\n* Diagnosed with any type of invasive cancer and have received systemic chemotherapy as part of their primary cancer treatment\n* Within the timeframe of 12 weeks to 1 year after the completion of their primary cancer treatment with curative intent. Primary treatment, in this context, includes surgery, radiotherapy, and\u002For chemotherapy. For patients undergoing endocrine, targeted, or immunotherapy, their treatment must not be scheduled to be discontinued within the next 6 months.\n* No evidence of distant metastatic disease (i.e., no diagnosis of metastatic disease in the regular clinical trajectory)\n* ECOG (Eastern Cooperative Oncology Group) performance status ≤ 2\n* Presence of at least one of the following side-effects: fatigue (measured using EORTC QLQ-C30 fatigue symptom scale, score \\>39), perceived low physical functioning in daily life (measured using EORTC QLQ-C30 physical functioning scale, score \\\u003C83), anxiety or depressive symptoms (measured using PHQ-ADS \\> 20), and\u002For CIPN (measured using 2 PRO-CTCAE items, score \\>0) for patients who received neurotoxic chemotherapy. Cut-off values are based on established thresholds.19-21\n* Access to good quality and stable internet connection to access the live-remote training sessions.\n* Able and willing to perform the exercise program and wear the activity tracker at least one week after T0 and before T2, T4, and T5 measurements and during training and online assessment sessions.\n* Able to read, speak and understand the main country language.\n\nExclusion Criteria:\n\nA potential subject who meets any of the following criteria will be excluded from participation in this study:\n\n* Too physically active (i.e., \\>210 minutes\u002Fweek of self-reported moderate-to-vigorous or leisure and sports activities; this threshold has also been used in other exercise RCTs, such as PREFERABLE-EFFECT22, and fits activity levels of all participating countries) or participation in an exercise program comparable to the LION exercise program.\n* Following, or planned to follow, a structured psychological intervention during the intervention period, i.e., cognitive behavioral therapy, or unstable on psychotropic medication\n* Participated in the intervention group of an exercise study during cancer treatment\n* Inability to complete the testing or training sessions or any other contraindications for exercise as determined by the treating physician, including:\n* Severe neurologic or cardiac impairment according to ACSM criteria\n* Uncontrolled severe respiratory insufficiency or dependence on oxygen suppletion in rest or during exercise\n* Uncontrolled pain All these exclusion criteria are formulated to ensure safe participation in the LION exercise program\n* Any circumstances that would impede ability to give informed consent or adherence to study requirements as determined by the treating physician\n* More than 1 week not able to attend training sessions during the LION intervention period","ALL","18 Years","100 Years",{"count":270,"type":271},350,"ESTIMATED","INTERVENTIONAL",[274],"NA","Background\n\nMany people with cancer face ongoing problems from their disease and treatments, like fatigue, reduced physical fitness, feeling anxious or down, and neuropathy. While exercise might help with these problems, most studies did not focus on tailoring exercise to address these specific complaints. Exercise programs under supervision (like with a trainer) seem to work better, but barriers for following such sessions are travel distance and time. Therefore, following an exercise program at home with a trainer guiding via video (live-remote) might be a good solution. But, it is unclear how effective this remote exercise program is for cancer patients.\n\nGoal of the study:\n\nThe main goal of this study is to assess the effectiveness of a personalized, live-remote exercise intervention for cancer survivors on quality of life and the patients' main complaint. The four complaints tackled in this study are: 1) fatigue, 2) reduced physical functioning, 3) anxiety and\u002For depressive symptoms, and 4) neuropathy.\n\nDesign of the study\n\nIn the LION study, 350 cancer patients will be randomly divided into the exercise group or control group. These patients all have at least one of these complaints: 1) fatigue, 2) reduced physical functioning, 3) anxiety and\u002For depressive symptoms, and\u002For 4) neuropathy. Patients cannot participate in the study if they are already very active.\n\nThe exercise group will start a 12-week exercise program right away, and the other group will wait for 12 weeks before starting. The exercise program consists of three sessions per week. Two sessions per week include aerobic training and strength training. These sessions will be followed by all patients; and aim to improve fitness and strength. The third session specifically aims at improvement of the main complaint, for example fatigue.\n\nParticipants will get an app and a fitness tracker to help them stay on track with their exercises. Furthermore, patients get information on the effects of exercise for cancer patients and why exercise is important for specific complaints.\n\nMeasurements\n\nThe main outcomes of this study are quality of life and the main side-effect of the patient. Other measurements include all kind of patient reported outcomes (like sleep problems and pain), physical fitness, muscle strength, balance, anthropometrics, and (inflammatory) markers in blood.\n\nConclusion:\n\nThis study investigates if personalized exercises done at home, with video guidance, can make cancer survivors feel better and manage their side effects more effectively.",[277],"Neoplasms",[279,280,281,282],"cancer survivors","exercise","live remote","personalized exercise training","2026-05-06",{"date":285,"type":286},"2026-05-11","ACTUAL",{"date":288,"type":286},"2024-02-14",{"date":290,"type":271},"2027-10-31",{"name":5,"class":6},1]